免疫特征与针对肌肉侵入性膀癌的新辅助化疗免疫疗法的反应有关
Wolfgang Beckabir1,2, Mi Zhou1,3, Jin Seok Lee1,3,4
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
针对肌肉侵入性膀癌 (MIBC) 的新辅助化疗免疫疗法显示出有希望的反应率. 血IL-9和特定的瘤标志物可以预测治疗的有效性,指导未来患者选择免疫检查点抑制剂.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 基因组学就是基因组学.
背景情况:
- 基于西斯的新辅助化疗是肌肉侵入性膀癌 (MIBC) 的标准.
- 免疫检查点抑制 (ICI) 和化学免疫疗法在新辅助环境中显示出前景.
- 在LCCC1520试验中,评估了用于MIBC的新辅助化学免疫疗法 (gemcitabine, cisplatin, pembrolizumab).
研究的目的:
- 报告来自LCCC1520试验的后期相关分析.
- 确定可预测对新辅助化学免疫疗法 (NAC-ICI) 反应的生物标志物.
- 为了比较NAC-ICI与新辅助ICI单独的潜在预测生物标志物.
主要方法:
- 第2期单臂试验 (LCCC1520) 与39名MIBC患者进行.
- 对瘤突变特征,免疫基因特征和RNA亚型的相关分析.
- 血IL-9的测量和瘤PD-L1,TIGIT,IL-8签名和RNA亚型的分析.
主要成果:
- 22/39名患者实现了病理反应 (下降阶段).
- 治疗改变了瘤突变特征和免疫基因特征.
- 增加的血IL-9,更高的PD-L1/TIGITRNA表达,IL-8签名和富含 strom的亚型与反应有关.
结论:
- 血IL-9是NAC-ICI反应的潜在预测生物标志物.
- 瘤IL-8特征和丰富的瘤亚型可以预测NAC-ICI对单独ICI的好处.
- 需要进一步发现和验证生物标志物,以优化患者选择ICI治疗.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
05:19Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
Published on: March 29, 2019
相关概念视频
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
The Tumor Microenvironment
